Inhaled dry powder mannitol in cystic fibrosis (CF): Microbiology results from the 6 month double-blind CF301 study Source: Annual Congress 2010 - Cystic fibrosis: lung disease infection and more Year: 2010
In vitro evaluation of the Twincer colistin dry powder inhaler as a non-cough-inducing alternative to Colobreathe Source: International Congress 2016 – Clinical and microbiological aspects of bronchiectasis and non-tuberculous mycobacterium (NTM) infections Year: 2016
The small airway inflammation of asthmatic patients who have used dry powder type inhaled steroid for moderate-long term evaluated by induced sputum and the efficacy of HFA-BDP (QVAR) inhalation Source: Eur Respir J 2005; 26: Suppl. 49, 503s Year: 2005
Systemic availability (lung deposition) of drug from two different dry powder inhalers in children with asthma Source: Eur Respir J 2002; 20: Suppl. 38, 429s Year: 2002
Peak inspiratory flow in COPD: implications for the use of dry powder inhalers Source: Eur Respir J 2001; 18: Suppl. 33, 134s Year: 2001
Are patients with cystic fibrosis of six years and older able to use dry powder inhalers? A study of the effect of device resistance on flows and volumes Source: Eur Respir J 2004; 24: Suppl. 48, 386s Year: 2004
Do dry powder inhalers (DPIs) have a ‘Goldilocks Zone’ of inhalation? In vitro lung deposition of Budesonide/Formoterol (BUD/FORM) DPI with different inhalation profiles Source: International Congress 2017 – Pulmonary drug and devices delivery Year: 2017
Peak inspiratory flow rate and slope of the inhalation profiles in dry powder inhalers Source: Eur Respir J 2001; 18: 780-783 Year: 2001
Inspiratory profiles and resistance of two dry powder inhalers in COPD patients Source: Eur Respir J 2004; 24: Suppl. 48, 291s Year: 2004
Prevalence of bronchoconstriction in patients with bronchiectasis assessed prior to treatment with a dry powder preparation of mannitol Source: Annual Congress 2007 - Current issues in airway physiology, pharmacology and monitoring Year: 2007
Improving inhalation parameters through dry powder inhalers (DPIs) after an acute asthma exacerbation Source: Annual Congress 2012 - Trials in asthma: asthma exacerbations and severe asthma Year: 2012
Assessment of peak inspiratory flow through dry powder inhalers in asthmatics Source: Eur Respir J 2002; 20: Suppl. 38, 542s Year: 2002
In vitro delivery of formoterol via a novel multi-dose dry powder inhaler, at clinically relevant inspiratory flow rates Source: Eur Respir J 2003; 22: Suppl. 45, 472s Year: 2003
Peak inspiratory flow rates in COPD patients with Easyhaler® dry powder inhaler Source: Annual Congress 2009 - New aspects of inhalation therapy Year: 2009
Consider the turbulent energy not inhalation flow when patients use dry powder inhalers (DPIs) Source: Annual Congress 2012 - The best of pharmacology treatments of airway diseases: new devices and drugs Year: 2012
Gamma-scintigraphic evaluation of the delivered dose, lung deposition rate and distribution pattern of 99m Tc-labelled tiotropium via dry powder inhaler Source: Eur Respir J 2003; 22: Suppl. 45, 475s Year: 2003
Inspiratory profiles and consistency of behaviour regarding dose delivery characteristics of two dry powder inhalers in COPD patients Source: Eur Respir J 2004; 24: Suppl. 48, 13s Year: 2004
Peak inspiratory flow rates through placebo dry powder inhaler device in various asthma and COPD patients Source: Annual Congress 2012 - Asthma management Year: 2012
The investigation of inhalation continuous duration for dry powder inhalers in asthmatic patients Source: Annual Congress 2012 - The best of pharmacology treatments of airway diseases: new devices and drugs Year: 2012
Efficacy and safety of ciprofloxacin dry powder for inhalation in patients with non-cystic fibrosis bronchiectasis Source: Annual Congress 2011 - Advances in antibiotic therapy of non-cystic fibrosis bronchiectasis Year: 2011